Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
James W. Murrough, Laili Soleimani, Kaitlin E. DeWilde, et al.
Psychological Medicine (2015) Vol. 45, Iss. 16, pp. 3571-3580
Closed Access | Times Cited: 276

Showing 1-25 of 276 citing articles:

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos, Ruin Moaddel, Patrick J. Morris, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 621-660
Open Access | Times Cited: 942
Suicide and suicide risk
Gustavo Turecki, David A. Brent, David Gunnell, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 776
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin, et al.
American Journal of Psychiatry (2018) Vol. 175, Iss. 7, pp. 620-630
Open Access | Times Cited: 588
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson, Elizabeth D. Ballard, Michael H. Bloch, et al.
American Journal of Psychiatry (2017) Vol. 175, Iss. 2, pp. 150-158
Open Access | Times Cited: 577
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 383-399
Open Access | Times Cited: 472
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short, Joanna Fong, Verònica Gálvez, et al.
The Lancet Psychiatry (2017) Vol. 5, Iss. 1, pp. 65-78
Closed Access | Times Cited: 448
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Kasper B. Hansen, Lonnie P. Wollmuth, Derek Bowie, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1469-1658
Open Access | Times Cited: 445
Targeting glutamate signalling in depression: progress and prospects
James W. Murrough, Chadi G. Abdallah, Sanjay J. Mathew
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 7, pp. 472-486
Closed Access | Times Cited: 412
Prognosis and improved outcomes in major depression: a review
Christoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 384
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Michael F. Grunebaum, Hanga Galfalvy, Tse‐Hwei Choo, et al.
American Journal of Psychiatry (2017) Vol. 175, Iss. 4, pp. 327-335
Open Access | Times Cited: 367
Ketamine: 50 Years of Modulating the Mind
Linda Li, Phillip E. Vlisides
Frontiers in Human Neuroscience (2016) Vol. 10
Open Access | Times Cited: 317
Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 286
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Helen Herrman, Vikram Patel, Christian Kieling, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 957-1022
Open Access | Times Cited: 283
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Allison C. Nugent, Elizabeth D. Ballard, Todd D. Gould, et al.
Molecular Psychiatry (2018) Vol. 24, Iss. 7, pp. 1040-1052
Open Access | Times Cited: 218
Blinding and expectancy confounds in psychedelic randomized controlled trials
Suresh Muthukumaraswamy, Anna Forsyth, Thomas Lumley
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 9, pp. 1133-1152
Closed Access | Times Cited: 209
Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Ying Xu, Maree L. Hackett, Gregory Carter, et al.
The International Journal of Neuropsychopharmacology (2015) Vol. 19, Iss. 4, pp. pyv124-pyv124
Open Access | Times Cited: 208
Treatment-resistant depression and suicidality
Isidoor O. Bergfeld, Mariska Mantione, Martijn Figee, et al.
Journal of Affective Disorders (2018) Vol. 235, pp. 362-367
Closed Access | Times Cited: 192
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Eduardo Ekman Schenberg
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 188
<p>Ketamine and depression: a narrative review</p>
Alexandrine Corriger, Gisèle Pickering
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3051-3067
Open Access | Times Cited: 184
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei Yan, Lijia Chang, Kenji Hashimoto
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 559-573
Open Access | Times Cited: 180
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 163
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
Wei Yao, Qianqian Cao, Shilin Luo, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 3, pp. 1618-1629
Open Access | Times Cited: 158
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
Lijia Chang, Kai Zhang, Yaoyu Pu, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 181, pp. 53-59
Closed Access | Times Cited: 147
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
Roger S. McIntyre, Isabelle P. Carvalho, Leanna M.W. Lui, et al.
Journal of Affective Disorders (2020) Vol. 276, pp. 576-584
Closed Access | Times Cited: 147
Page 1 - Next Page

Scroll to top